NEW YORK – Ideaya Biosciences said Monday that it plans to develop a KAT6/7 inhibitor, IDE251, as treatment for breast and lung cancer patients whose tumors harbor 8p11 amplifications.
The South San Francisco, California-based firm is planning to file an investigational new drug application with the US Food and Drug Administration in 2025 for IDE251, which would allow it to evaluate the candidate in clinical trials.
The firm believes that the agent could lead to durable anti-tumor activity in the 15 percent of breast cancer and 17.5 percent of non-small cell lung cancer patients whose cancers harbor 8p11 amplifications.
IDE251 is designed to inhibit the two epigenetic modulators KAT6 and KAT7, while sparing structurally similar KAT modulators. Preclinical models have suggested that the response may be enriched in patients with 8p11 amplifications.
The agent is the eighth candidate that the firm has announced. The news of IDE251 comes after Ideaya said last week that it has treated the first endometrial cancer patient in a Phase I clinical trial of another candidate, the PARG inhibitor IDE161, combined with Merck's checkpoint inhibitor Keytruda (pembrolizumab).
The firm is evaluating the combination in patients with both microsatellite instability-high and microsatellite-stable endometrial cancers.